|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Lutetium-617 - Treatment Sequencing Considerations for Metastatic Castration-Resistant Prostate Cancer
|
Neal D. Shore, MD, FACS
Neal Shore joins Alicia Morgans to discuss sequencing strategies to implement lutetium-617 for patients with metastatic castration-resistant prostate cancer (mCRPC).
|
|
|
|
|
|
|
|
|
|
|
| Imaging and PET Analysis as a Prognostic Tool for Lu-PSMA-617 Treatment in Patients with mCRPC |
Phillip H. Kuo, MD, Ph.D.,
Phillip Kuo joins Alicia Morgans to discuss recent findings in a VISION sub-study. Dr. Kuo explains how this post-hoc exploratory analysis of the PSMA PET scans that were done for the VISION trial resulted in a better understanding of which patients are likely to respond better to treatment with lutetium-PSMA-617. |
|
|
|
|
|
|
|
|
|
|
|
The Implementation of PSMA Theranostics in Clinical Practice
|
A. Oliver Sartor, MD
Oliver Sartor joins Alicia Morgans in a discussion on the implementation of PSMA theranostics and treating patients with lutetium in clinical practices. Drs. Morgans and Sartor talk through the logistics of this integration, patient selection, and treatment choice for prolonging survival and improving quality of life.
|
|
|
|
|
|
|
|
|
|
|
| Even with New Treatment Advances for Metastatic Castration-Sensitive Prostate Cancer, There Is Still Opportunity to Bring in Radiopharmaceutical Therapy |
| Evan Yu, MD |
| Evan Yu highlights the concept of adding radiopharmaceutical agents to therapy for patients with mCSPC. We’ve previously seen the alpha-particle emitting radiopharmaceutical, radium-223, offer an overall survival, symptomatic skeletal events, and quality of life benefits for patients with bone metastatic castration-resistant prostate cancer (mCRPC) and symptoms. However, a practical challenge is that radium-223 is often administered to heavily pre-treated patients very late in the mCRPC disease state, in a rather palliative setting. |
|
|
|
|
|
| [68Ga]Ga-PSMA-11 PET Baseline Imaging as a Prognostic Tool for Clinical Outcomes to [177Lu]Lu-PSMA-617 in Patients With mCRPC: A VISION Substudy |
| Andrew J. Armstrong, MD, MSc |
| Andrew J. Armstrong discusses the prognostic value of baseline [68Ga]Ga-PSMA-11 PET imaging in men undergoing theranostic treatment with 177Lu-PSMA-617 for heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) in the VISION trial. These data support the use of 68Ga-PSMA-11 to identify men with mCRPC who most benefit from PSMA-targeted theranostic treatment. |
|
|
|
|
|
| Best Use of Lutetium-PSMA and Where To Put It in Sequencing Therapies Including Treatment Monitoring
|
| Charles J. Ryan, MD
|
| Charles Ryan discusses the best use of Lutetium-PSMA and where to place it when sequencing therapies, including treatment monitoring. There is early evidence that there may be activity of alpha emitter therapy after beta therapy. Among patients receiving Actinium-225-PSMA-617 who had previously failed 177Lu-PSMA-617 targeted radioligand therapy, there was a high-rate of response (62%), but these responses were short-lived and toxicity was high (xerostomia, hematologic adverse events.
|
|
|
|
|
|
|
|
|
|
|
| The Role of PSMA PET in mCRPC and PSMA-Radioligand Therapy
|
| Neil Fleshner, MD, MPH, FRCSC
|
| Neil Fleshner discusses the role of PSMA-PET imaging in metastatic castration-resistant prostate cancer (mCRPC) and PSMA-radioligand therapy. Dr. Fleshner emphasized that PSMA-PET imaging is here to stay and will have an evolving role in advanced prostate cancer. While it is helpful for staging patients with CRPC, the added value is unclear.
|
|
|
|
|
|
| PSMA Theranostics and Novel Approaches to Treatment in mCRPC
|
| Alicia K. Morgans, MD, MPH
|
| The 37th Annual European Association of Urology Congress held in Amsterdam, The Netherlands between July 1st, and 4th 2022 was host to a session about innovative future treatment options for metastatic castration-resistant prostate cancer (mCRPC). Dr. Alicia Morgans was tasked with discussing prostate-specific membrane antigen (PSMA) theranostics and novel approaches to the treatment of metastatic castration-resistant prostate cancer (mCRPC).
|
|
|
|
|
|
| Efficacy and Safety of 177Lu-PNT2002 Prostate-Specific Membrane Antigen (PSMA) Therapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Initial Results from SPLASH
|
| Aaron Hansen, BSc, MBBS, FRACP
|
| Aaron Hansen presents the first, preliminary results of the SPLASH trial assessing the radioligand 177Lu-PNT2002 (also known as 177Lu-PSMA I&T) in PSMA-positive patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who progressed after treatment with androgen receptor axis-targeted therapy (ARAT). This first analysis presents the lead-in component of the phase 3 SPLASH trial.
|
|
|
|
|
|
|
